PE20142437A1 - Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino - Google Patents

Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino

Info

Publication number
PE20142437A1
PE20142437A1 PE2014001785A PE2014001785A PE20142437A1 PE 20142437 A1 PE20142437 A1 PE 20142437A1 PE 2014001785 A PE2014001785 A PE 2014001785A PE 2014001785 A PE2014001785 A PE 2014001785A PE 20142437 A1 PE20142437 A1 PE 20142437A1
Authority
PE
Peru
Prior art keywords
methyl
treatment
espirox
onas
methylen
Prior art date
Application number
PE2014001785A
Other languages
English (en)
Inventor
Norbert Schmees
Lars Rose
Tuula Valo
Katja Prelle
Reinhard Nubbemeyer
Henriikka Korolainen
Harri Jukarainen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142437(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20142437A1 publication Critical patent/PE20142437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referida a un compuesto derivado de 18-metil-15(beta),16(beta)-metilen-19-nor-20-espirox-4-en-3-onas de formula general (1), donde R6 y R7 son hidrogeno o un grupo metileno. Tambien esta referida a un sistema intrauterino que comprende el compuesto de formula 1. Dichos compuestos son utiles en el tratamiento de la menorragia, de hemorragias intrauterinas en general, entre otros
PE2014001785A 2012-04-23 2013-04-19 Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino PE20142437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012206653 2012-04-23

Publications (1)

Publication Number Publication Date
PE20142437A1 true PE20142437A1 (es) 2015-01-31

Family

ID=48141995

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001785A PE20142437A1 (es) 2012-04-23 2013-04-19 Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino

Country Status (28)

Country Link
US (1) US20150119372A1 (es)
EP (1) EP2841073A1 (es)
JP (1) JP2015514789A (es)
KR (1) KR20150005548A (es)
CN (1) CN104379149A (es)
AR (1) AR090800A1 (es)
AU (1) AU2013251842A1 (es)
BR (1) BR112014026086A2 (es)
CA (1) CA2871001A1 (es)
CL (1) CL2014002857A1 (es)
CO (1) CO7111253A2 (es)
CR (1) CR20140489A (es)
CU (1) CU20140120A7 (es)
DO (1) DOP2014000240A (es)
EA (1) EA201491917A1 (es)
EC (1) ECSP14024263A (es)
GT (1) GT201400225A (es)
HK (1) HK1206271A1 (es)
IL (1) IL235096A0 (es)
MA (1) MA37443A1 (es)
MX (1) MX2014012848A (es)
PE (1) PE20142437A1 (es)
PH (1) PH12014502371A1 (es)
SG (1) SG11201406583QA (es)
TN (1) TN2014000445A1 (es)
TW (1) TW201345530A (es)
UY (1) UY34759A (es)
WO (1) WO2013160200A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120754109B (zh) * 2024-11-08 2026-04-28 广州医科大学 β-榄香酮酸或其衍生物在制备预防和/或治疗多囊卵巢综合征药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
DE102006030416A1 (de) 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
CA2871001A1 (en) 2013-10-31
JP2015514789A (ja) 2015-05-21
CR20140489A (es) 2014-12-24
BR112014026086A2 (pt) 2017-07-18
AR090800A1 (es) 2014-12-10
EA201491917A1 (ru) 2015-04-30
CL2014002857A1 (es) 2015-02-06
CO7111253A2 (es) 2014-11-10
MX2014012848A (es) 2015-02-05
CN104379149A (zh) 2015-02-25
EP2841073A1 (de) 2015-03-04
US20150119372A1 (en) 2015-04-30
DOP2014000240A (es) 2015-02-15
SG11201406583QA (en) 2014-11-27
TN2014000445A1 (en) 2016-03-30
CU20140120A7 (es) 2015-02-26
ECSP14024263A (es) 2015-12-31
AU2013251842A1 (en) 2014-11-06
PH12014502371A1 (en) 2015-01-12
GT201400225A (es) 2016-01-22
HK1206271A1 (en) 2016-01-08
TW201345530A (zh) 2013-11-16
WO2013160200A1 (de) 2013-10-31
MA37443A1 (fr) 2016-05-31
IL235096A0 (en) 2014-12-31
UY34759A (es) 2013-11-29
KR20150005548A (ko) 2015-01-14

Similar Documents

Publication Publication Date Title
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
DOP2016000089A (es) Sistema de administracion intrauterina
CO7350653A2 (es) Retinoides y uso de los mismos
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
MX394430B (es) Proceso para la preparación de 5-fluoro-1h-pirazoles.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
GT201400146A (es) Composiciones farmacéuticas tópicas que comprenden bexaroteno y corticosteroides
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
ECSP14024263A (es) USO DE 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS EN EL TRATAMIENTO DE MENORRAGIA, Y SISTEMAS INTRAUTERINOS QUE COMPRENDEN 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS PARA EL TRATAMIENTO DE TRASTORNOS CON SANGRADO UTERINO
PE20142438A1 (es) Uso intrauterino de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-onas, sistemas intrauterinos que contienen 18-metil-15b,16b-metilen-19-nor-20-espiox-4-en-3-onas, asi como su uso en la anticoncepcion y terapia ginecologica
CL2016000586A1 (es) Composición que comprende fósforo para uso en prevenir deformidades en peces triploides
AR098060A1 (es) Sistema de administración intrauterina
ECSP15040690A (es) Inhibidores de histona desmetilasas

Legal Events

Date Code Title Description
FC Refusal